# US 2025/0144248 A1 · Methods and systems for improved nucleic acid delivery via ultrasound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144248 A1
- Document ID: US20250144248A1
- Status: Published application
- Kind: A1
- Application number: 18/937,809
- Filed: 2024-11-05
- Published: 2025-05-08
- Earliest claimed: 2023-11-07
- Assignees: SonoThera, Inc.
- Applicants: SonoThera, Inc.
- Inventors: Steven B. FEINSTEIN; Kenneth GREENBERG; Chuan FU; Ivan KRIVEGA; Maria KONOVALENKO; Barry CAMPBELL; Zoya GLUZMAN-POLTORAK; David SATYADI; Margarita KRIVEGA
- Web page: https://patentgrep.com/patent/US20250144248A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 41/0023: {Aggression treatment or altering}
- A61K 41/0047: {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are methods, compositions, and kits for improving a delivery of a nucleic acid to a cell in an organ of a subject. Such methods, compositions, and kits may include a sonoactive agent and a nucleic acid comprising a cargo polynucleotide and a nuclear localization element and/or an innate immune response avoidance moiety, which may be an aptamer. Delivery may involve sonoporation.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4

A method for expressing a nucleic acid in a target cell of a subject, the method comprising administering to the subject the nucleic acid, wherein the nucleic acid comprises a cargo polynucleotide and a nuclear localization element, wherein the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 1.25 fold as compared to a nucleic acid lacking the nuclear localization element.

### Claim at position 3

5-6. (canceled)

### Claim 7 (depends on 4)

The method of claim 4, further comprising administering ultrasonic acoustic energy to the target cell of the subject.

### Claim 8 (depends on 7)

The method of claim 7, further comprising administering a sonoactive agent to the subject.

### Claim 9

(canceled)

### Claim 10 (depends on 4)

The method of claim 4, wherein the nuclear localization element increases expression of the cargo polynucleotide in the target cell by at least 1.35, 1.40, at least 1.45, at least 1.50, at least 1.55, at least 1.60, at least 1.65, at least 1.75, at least 1.80, at least 1.85, at least 1.90, at least 1.95, at least 2.0, at least 2.25, at least 2.5, at least 2.75, at least 3, at least 3.5, at least 4, at least 4.5, or at least 5 fold as compared to a nucleic acid lacking the nuclear localization element.

### Claim 11

(canceled)

### Claim 12 (depends on 4)

The method of claim 4, wherein the nuclear localization element comprises an aptamer.

### Claim 13 (depends on 12)

The method of claim 12, wherein the aptamer is a DNA aptamer.

### Claim at position 11

14-23. (canceled)

### Claim 24 (depends on 12)

The method of claim 12, wherein the aptamer comprises a sequence configured to bind nucleolin.

### Claim at position 13

25-26. (canceled)

### Claim 27 (depends on 12)

The method of claim 12, wherein the aptamer comprises a sequence configured to bind an importin protein.

### Claim 28 (depends on 27)

The method of claim 27, wherein the sequence configured to bind the importin protein comprises a nucleic acid sequence of SEQ ID NO: 48, 129, OR 130.

### Claim 29 (depends on 12)

The method of claim 12, wherein the nuclear localization element or the aptamer comprises a sequence configured to bind a nucleoporin protein.

### Claim 30 (depends on 29)

The method of claim 29, wherein the nucleoporin protein is positioned on a cytoplasmic ring or a cytoplasmic filament of the nuclear pore complex.

### Claim 31 (depends on 29)

The method of claim 29, wherein the nucleoporin protein comprises NUP 214, NUP 88, or NUP 358.

### Claim 32 (depends on 29)

The method of claim 29, wherein the nucleoporin protein comprises NUP 358.

### Claim 33 (depends on 29)

The method of claim 29, wherein the sequence configured to bind the nucleoporin protein comprises a nucleic acid sequence of any one of SEQ ID NO: 49-50.

### Claim at position 21

34-79. (canceled)

### Claim 80 (depends on 12)

The method of claim 12, wherein the nucleic acid is a closed linear DNA construct comprising a stem region comprising a double stranded DNA sequence covalently closed at both ends by hairpin loops.

### Claim 81 (depends on 80)

The method of claim 80, wherein the hairpin loops are single-stranded.

### Claim 82 (depends on 80)

The method of claim 80, wherein the hairpin loops form a stem region of the aptamer.

### Claim 83 (depends on 80)

The method of claim 80, wherein the hairpin loops comprise the aptamer.

### Claim at position 26

84-120. (canceled)

### Claim 121

A pharmaceutical composition comprising:
a. a microbubble; and
b. a nucleic acid comprising (1) a cargo polynucleotide comprising an expression cassette that comprises a therapeutic transgene and (2) an aptamer, wherein the aptamer comprises a sequence configured to increase nuclear localization.

### Claim at position 28

122-248. (canceled)

### Claim 249

An isolated nucleic acid comprising: a cargo polynucleotide comprising an expression cassette that encodes a therapeutic transgene configured for expression in a target cell of a subject, and a nuclear localization element configured to increase expression of the cargo polynucleotide in the target cell.

### Claim at position 30

250-297. (canceled)
